BioTek is pleased to announce the availability of customizable pre-programmed protocols for Gen5™ Data Analysis Software designed to estimate Relative Potency according to the requirements of the USDA APHIS Center for Veterinary Biologics (CVB) guidelines published March 14, 2014.
The CVBSOP0101.01 establishes the criteria that veterinary vaccine producers must use to estimate the relative potency of their test serials prior to submission for licensing through the CVB. Several pre-programmed Gen5 protocols addressing both the full dose response and the linear methods for calculation are available for free download from BioTek’s website. BioTek’s Gen5 capability provides CVB compliant laboratories with a convenient option to meet the stringent requirements of this SOP.
BioTek will be hosting a webinar on September 25, 2014 where they will describe the use of Gen5 software to estimate relative potency values per the CVB requirements. Registration for the webinar can be accessed here.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. These technologies are used to aid life science research, facilitate drug discovery, provide rapid and cost-effective analysis, and enable sensitive, accurate quantification of molecules across diverse applications. BioTek espouses a “Think Possible” approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations. As such, they are often honored for local accomplishments and technological innovations, including Best Places to Work in Vermont, Frost & Sullivan North American New Product Innovation Award for Workflow Solutions in Life Sciences, SelectScience’s Drug Discovery Product of the Year – Scientists' Choice Award, and a Silver Edison Award for the Cytation Cell Imaging Multi-Mode Reader.